Overview
Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)
Status:
Terminated
Terminated
Trial end date:
2017-11-23
2017-11-23
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study including two parts,one part is a randomized clinical trial design,another part is a registration study.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Qidong Gaitianli Medicines Co., Ltd
Criteria
Inclusion Criteria:- Patients with complete resection who are at TNM (primary tumor, regional nodes,
metastasis) stage II-Ⅲa, postoperative pathology confirmed for non-small cell lung
cancer;
- Has completed four cycle standard solution of adjuvant chemotherapy, or refused to
accept the postoperative adjuvant chemotherapy;
- Patients between 18 and 70 years old, no gender restriction;
- Eastern Cooperative Oncology Group (ECOG) PS of two or less;
- Before the start of the study, patient fully understands the study and is willing to
sign the informed consent form;
Exclusion Criteria:
- Receiving adjuvant chemotherapy patients started greater than 24 weeks from surgical
resection;
- Refused adjuvant chemotherapy patients started greater than 8 weeks from surgical
resection;
- Suspected malignant pleural effusion;
- There is no clear pathological diagnosis;
- Combined with other cancer;
- Patient have a positive surgical margin;
- Accept other treatment for lung cancer of postoperative;
- Combined with severe idiopathic disease of liver, kidney and hematopoietic system;
- Combined psychosis or AIDS;
- Allergy to the test drug;
- Pregnant or lactating women;
- Participation in any other clinical trial within three months;
- Conditions that are considered not suitable for this study investigators.